Skip to main content
Journal cover image

FDA jeopardizes the lives of lung transplant recipients and in the process severely increases the cost to develop new immunosuppression.

Publication ,  Journal Article
Klintmalm, GB; Kaplan, B; Kirk, AD
Published in: Am J Transplant
April 2019

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Transplant

DOI

EISSN

1600-6143

Publication Date

April 2019

Volume

19

Issue

4

Start / End Page

971 / 972

Location

United States

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Transplant Recipients
  • Surgery
  • Lung Transplantation
  • Liver
  • Immunosuppressive Agents
  • Humans
  • Drug Costs
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Klintmalm, G. B., Kaplan, B., & Kirk, A. D. (2019). FDA jeopardizes the lives of lung transplant recipients and in the process severely increases the cost to develop new immunosuppression. Am J Transplant, 19(4), 971–972. https://doi.org/10.1111/ajt.15215
Klintmalm, Goran B., Bruce Kaplan, and Allan D. Kirk. “FDA jeopardizes the lives of lung transplant recipients and in the process severely increases the cost to develop new immunosuppression.Am J Transplant 19, no. 4 (April 2019): 971–72. https://doi.org/10.1111/ajt.15215.
Klintmalm, Goran B., et al. “FDA jeopardizes the lives of lung transplant recipients and in the process severely increases the cost to develop new immunosuppression.Am J Transplant, vol. 19, no. 4, Apr. 2019, pp. 971–72. Pubmed, doi:10.1111/ajt.15215.
Journal cover image

Published In

Am J Transplant

DOI

EISSN

1600-6143

Publication Date

April 2019

Volume

19

Issue

4

Start / End Page

971 / 972

Location

United States

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Transplant Recipients
  • Surgery
  • Lung Transplantation
  • Liver
  • Immunosuppressive Agents
  • Humans
  • Drug Costs
  • 3204 Immunology